Cardium Therapeutics, a health sciences and regenerative medicine company, today announced its research collaboration with researchers at Boston Children’s Hospital to assess the medical utility of Cardium’s Excellagen® to repair prenatally diagnosed birth defects using mesenchymal fetal stem cells for tissue grafting for transplantation.
“Boston Children’s team has made remarkable progress in the field of tissue regeneration and surgical repair of prenatally diagnosed congenital defects. We believe that Excellagen has an opportunity serve as a delivery platform in the field of stem cell therapy and we look forward to continuing to work with the Boston Children’s team to help make their innovative therapeutic vision a new standard of care, and potentially advance stem cell therapies toward commercialization,” Christopher J. Reinhard, CEO of Cardium, stated in the press release. “Excellagen was specifically designed to support advanced biologics and this new application further highlights its potential versatility as an important delivery agent for a variety of innovative therapeutic applications.”
Mesenchymal stem cells have the ability to develop into a variety of cell types. The collaboration aims to reverse life-threatening birth defects by using mesenchymal fetal stem cells derived prenatally from an infant’s amniotic fluid, the placenta, or umbilical cord blood and then seed the stem cells into a scaffold to promote the growth of an engineered tissue graft.
As the company explains, these grafts will potentially be used to surgically repair, either in the fetus or immediately after birth, certain prenatally diagnosed birth defects such as congenital diaphragmatic hernia, tracheal and chest wall defects, bladder extrophy, and various cardiac anomalies.
In preliminary pre-clinical research, Excellagen collagen homogenate has demonstrated its ability to maintain mesenchymal fetal stem cell viability. Cardium is currently conducting additional proof-of-concept studies.
Excellagen is an FDA-approved homogenate that represents a new product delivery platform for the potential development of a portfolio of advanced tissue regeneration therapeutic opportunities that could include anti-infectives, antibiotics, peptides, proteins, small molecules, DNA, stem cells, differentiated cells, and conditioned cell media.
Excellagen’s FDA clearance provides for very broad labeling including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, as well as surgical, trauma, and draining wounds.
For more information, visit www.cardiumthx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment